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Traditionally, probiotics are live microorganisms that are considered to be both beneficial and safe.
Unfortunately, their effects may be short-lived, inconsequential, or ambiguous. Some symbiotic (probiotic)
microorganisms with known health benefits may cause opportunistic infections, increase incidence of
allergic sensitization and autoimmune disorders, produce microecological imbalance, modify gene expression,
transfer genes that are virulent and resistant to antibiotics, cause disorders in epigenome and genome
integrity, induce chromosomal DNA damage, and activate signaling pathways associated with cancer
and other chronic diseases. As of now, the commercially available probiotics serve as a first-generation
means of correcting microecological disorders. Further development will include the selection of natural
metabiotics and/or formulation of synthetic (or semi-synthetic) metabiotics that will be analogies or
improvised versions of natural bioactives, produced by symbiotic (probiotic) microorganisms. Metabiotics
are structural components of probiotic microorganisms and/or formulation of and/or signaling molecules
with a determined (known) chemical structure that can optimize host-specific physiological functions and
regulate metabolic and/or behavior reactions connected with the activity of host indigenous microbiota.
Metabiotics are advantageous because of their chemical structure, dosage, safety, and long shelf-life. Thus,
metabiotics should not be considered a myth; they are the result of the natural evolution of probiotic
conception.
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Neither microbial genes nor microbial names cause
any harm to the body, but microbial products may
do. The presence of very active microbial biological
compounds in the gut may have physiological and
pathophysiological consequences for the host. Tore
Midtvedt (2008)
According to modern scientific doctrine, the human
being is a ‘superorganism’  a consortium of numerous
Eukarya, Bacteria, Archaea, and Viruses. Various indigen-
oushostmicroorganismsshouldbeconsideredasessential
complex extracorporal physiological systems playing a
fundamental role in human health and disease. Host
microbiota and other functional and metabolic systems
connected with host eukaryotic cells are working together
profitably for the whole organism and for its separate
components. Unfortunately, various unfavorable biotic or
abiotic factors and stress agents (diet, age, sex, pharma-
ceutical interventions, surgical interventions, etc.) can
produce microecological disorders, resulting in tissue,
organ, and regulatory system disturbances that can lead
toenhanced riskof disease development (15). This means
that the modulation of microbemicrobe and microbe
host interactions is an extremely important, fundamental,
andconcrete problemin modernbiologyandmedicine.To
date,tomaintainandrestorethegutmicrobialcommunity,
three therapeutic approaches have been used: probiotics,
prebiotics, and synbiotics (4, 610). As defined by FAO/
WHO, probiotics are non-pathogenic live microorganisms
which, when administered in adequate quantities, offer
health benefits to the host (6). Many therapeutics, dietary
foods, and additives containing probiotic microorganisms
have been introduced in practice for human health
support; for acute, chronic, localized, and systemic disease
prophylaxis; and for treating acute or chronic diarrhea,
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and cancer (5, 11). In the past decade, transplantation of
the distal gut microbiota (fecal bacteriotherapy) has
become popular in the treatment of some inflammatory
intestinal diseases (12, 13). The introduction of genetically
engineered probiotics based on recombinant live micro-
organisms in medical practice has also been actively
discussed (4).
Undesired properties and adverse affects
of live probiotic microorganisms
Although, more than 50 years’ use of probiotics has
shown them to be safe and beneficial, we are yet to define
the optimal amount of bacteria for probiotic effects; there
is no single mechanism of action for all probiotics.
Moreover, the beneficial effects of probiotics may be
short-lived, inconsequential, or ambiguous (3, 7, 14). The
latter may be explained by the low concentration of
biologically active probiotic substances (bioactives) found
in target places during the traditional application of live
probiotic microorganisms. The number of these microbial
bioactives produced may be inadequate to receive desir-
able specific effects under in vivo conditions (4, 7). Besides,
various molecules produced in volume by live probiotic
cells may interact with different receptors of indigenous
microbes and host cells, simultaneously resulting in both
beneficial and detrimental effects (15). Modern ‘omic’-
technologies have revealed substantial diversity of the gut
microbiome between individuals. Only a few microbial
phylotypes (species) are common to all individuals about
80% of human intestinal microorganisms in the adult gut
are individual at the strain level (7, 10, 1619). Experi-
mental and clinical studies published in recent years have
demonstrated that it is very difficult, if not impossible, to
produce industrially adequate probiotics for supporting
indigenous microflora at the optimal level by the simple
mechanical selection of a separate or combined set of
probiotic microorganism strains. Furthermore, limited
knowledge about the affect mechanisms of such bio-
therapeutics on the host gut microbiota, physiology, and
metabolism hampers the design of effective probiotics.
However, little is known about the molecular mechanisms
of probiotic effects (10, 15, 20).
In recent years, our knowledge on the safety of
probiotics has increased. It is necessary to bear in mind
that any detrimental and harmful consequences may
become apparent only after extended periods of probiotic
use. In reality, some data now show that not all probiotic
bacteria are safe, even if they belong to the Lactobacillus
or Bifidobacterium species with no traditional genes
of pathogenicity (21, 22). From medical reports it can
be inferred that lactic acid bacteria and even bifidobac-
teria used as microbial food cultures or probiotics are
rarely associated with human opportunistic infections
(infective endocarditis, sepsis, bacteraemia, pneumonia,
abdominal abscesses, peritonitis, meningitis, urological
infections, rheumatic vascular diseases), especially in
patients receiving antibiotic treatment or those who are
severely immune compromised (2128). There are in-
creased incidences of these bacteria being responsible
for allergic sensitization and autoimmune disorders (23,
2932). Symbiotic microorganisms (including probiotic
strains) sometimes can increase platelet aggregation
aggravating hemolytic uremic syndrome (21, 26); some
of them may be a source of toxic metabolites (e.g.
biogenic amines) (22). Probiotics found on living
microbes when introduced into gastro-intestinal or vagi-
nal tracts may cause unintended harm by gaining a
competitive advantage and causing ecological imbalance
by the microbe biodiversity and metabolic pathways. The
vast majority of probiotic strains introduced in practice
have been selected on the basis of their strong antag-
onistic activities against disease causative microorgan-
isms, it seems that many probiotics can suppress the
growth and development of human gut and vaginal
lactobacilli as well as other different indigenous micro-
biota (33, 34). They may also alter intestinal metabolism
due to their microbial enzymatic activities (35). It is
necessary also to remember that some intestinal micro-
bial strains can participate in the transformation of some
drugs, modifying their activity and/or converting the
prodrug to the active product (3638). Unfortunately,
nothing is known about interactions of live probiotic mic-
roorganisms with drug function in vitro and in vivo. The
situation becomes more complicated when new strains
belonging to Enterococcus, Streptococcus, Escherichia,
Bacillus, Bacteroides, or other microbial genera are
suggested as potential probiotics, including probiotics
that consist of multistrains or are constructed based on
genetically modified microorganisms. There are data that
probiotics (Lactobacillus GG) inside the intestinal tract
can induce the expression of more than 400 new genes
involved in immune response and inflammation, cell
growth and differentiation, apoptosis, cell-to-cell signal-
ing, and cell adhesion, resulting in a wider impact on the
host’s gene expression than thought of before the era of
macroarray technologies (39).
Oral introduction of Enterococcus faecalis modulates
activities of 42 genes in the gut epithelial cells; these genes
are involved in the regulation of the cell cycle, cell death,
and signaling (40). It has also been shown that, during
the passage through the intestinal tract, some silent genes
of probiotic bacteria may also be induced by host cell
signals; newly formed bacterial products are poorly
characterized, both chemically and functionally (39, 41,
42). For example, the induction of 72 probiotic L.
plantarum WSFS1 genes was demonstrated in these
conditions: nine genes were responsible for sugar trans-
port and the production of different enzymes involved in
their fermentation; nine genes were responsible for the
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vitamins; four genes were responsible for outer cell
proteins controlling resistance to specific host factors;
and 46 genes were responsible for the production of non-
identified proteins (42). It means that the probiotic cells
inside the gastrointestinal tract may be involved in the
interaction with various host-specific networks, for
example, participation in the degradation and production
of different nutrients by different metabolic pathways
in the small intestine and colon (18, 43), or in the
modification of immune response, cell differentiation, cell
signaling, adhesion (18, 44), cell proliferation, tissue
development, water and ion metabolism, balance of
Th1/Th2 cells, and so on (15, 45). Thus, it can be
expected that the expression of known or silent microbial
and eukaryotic genes may lead to undesirable effects on
human health.
In recent years, evidence has appeared that horizontal
gene transfer may take place between lactic acid bacteria
and enteric bacteria as well as between different lactic
acid bacteria. Natural gene transfer usually occurs via the
uptake of naked DNA (transformation), viruses (trans-
duction), or plasmids (conjugation). It is well-known that
the spread of antibiotic resistance is a major global health
issue (46). Probiotic bacteria can possess acquired anti-
biotic resistance genes associated with mobile genetic
elements (plasmids, transposons) that permit these or-
ganisms to transfer this genetic information to strains of
the same species, different species, or even different
genera, including both commensals and pathogens.
Such recombination events might not only result in the
distribution of undesired genes among intestinal micro-
organisms but can also produce rearrangements in
microbial genomes and change gene expression patterns
in recipient bacteria. The gene transfer and recombina-
tion events associated with probiotics may have long-
term environmental and health consequences (21, 22, 26,
46), including chromosome rearrangement and death of
recipient cells (47), alteration of the genomic and epi-
genomic regulation of gene expression, post-translation
modification of gene products, and host/microbial cross
talk resulting in the change of human metabolic and
behavior reactions (20, 48). Recently, it has been shown
(on the E. coli model) that the DNA methyltransferases
represent potential threats to the epigenomic integrity of
cell genomes. When the methylation system enters the cell
and begins to methylate the host genome, the methylated
DNA-specific microbial DNAse senses the epigenetic
changes, causing cell death via chromosomal cleavage
(49). Traditional virulence traits should not be present in
microorganisms used in food fermentation and probiotics
(21, 22).
Investigations made during the last decade have shown
that some human symbiotic microorganisms can produce
substances possessing genotoxic affects in intestinal
epithelial cell DNA. Therefore, some commensals
(including probiotic strain E. coli Nissle 1917) possess a
set of genes (pks island) that are responsible for the
production of double-strand breaks in host cell DNA.
Bacteria containing the pks genes induce in eukaryotic
cells a process called megalocytosis, in which the cell
body and nucleus become enlarged and mitosis stops.
Sometimes, 4 hours is enough for the pks island carrying
bacteria with eukaryotic cells to prompt an increase
in the DNA double-strand break level. A total of 34% of
E. coli strains isolated from healthy human intestine
content had such pks islands. A small number of bacterial
cells caused minimal DNA damage in eukaryotic cells; in
contrast, exposure to 100 or more bacteria per cell has
broken down the most nuclear DNA. Thus, the breaks in
host cell DNA caused by peptide-polyketide genotoxins
of some indigenous (probiotic) bacteria could trigger the
various cell disorders, including intestinal cancer devel-
opment (50, 51).
Live cells of E. faecalis being inside the intestinal tract
release substantial extracellular superoxide, hydroxyl
radical, and H2O2 during carbohydrate fermentation
and via autoxidation of membrane demethylmenaqui-
none. These oxidants can damage DNA and facilitate
development of sporadic adenomatous polyps and color-
ectal cancer (40, 52). Ethanol and its first metabolite
acetaldehyde have been recently classified as a class I
carcinogen. The acetaldehyde concentration required for
a mutagenic DNA effect increases from 100 to 500 mM.
Many microbes (including lactic acid bacteria) used as
microbial food cultures in fermented food products and
in the manufacture of probiotics can convert ethanol and/
or glucose to carcinogenic acetaldehyde. The acetalde-
hyde levels formed may exceed the aforementioned levels
markedly. Furthermore, because probiotic bacteria can
colonize the intestinal tract for a long period of time and
produce carcinogenic acetaldehyde locally, they can
potentially be more dangerous than traditional dairy
lactic acid bacteria because of increased total exposure to
this bacterial metabolite (53, 54).
Some scientists consider that ‘genetic engineering of
the human microbiota will enable to endow its members
with new desirable functions that treat diseases or
promote health’ (10). In spite of the scientific attractive-
ness of this idea, from a prolonged point of view, the mass
introduction of genetically engineered live probiotic
microbes in practice may have extremely dangerous
ecological and medical consequences even when using
such novel platform of microbial cells design as synthetic
biology approaches. Thus, the aforementioned data and
discussion indicate that the present knowledge on pro-
biotics is inadequate for any reliable ecological and
clinical risk assessment of short- and long-term conse-
quences; they could in fact often be unpredictable. Up to
now, we have no sufficient scientific knowledge to
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immune, and metabolic systems in an exactly predictable
manner by the administration of live probiotics (includ-
ing gene engineering), especially to infants and young
children (26, 35). The public should have the right to
participate in a discussion concerning known and poten-
tially undesired properties of probiotics made based on
living microorganisms and have information regarding
the unpredictable consequences of their long-term use.
Metabiotic concept
Although the history of live probiotic use does not high-
light any area of serious concern, recent well-documented
events of adverse effects and uncertainty about the level of
their risk require new alternative approaches in prophy-
laxis and treatment of pathological conditions associated
with the imbalance of host microbiota. These approaches
have to retain and improve the positive accumulated
experience of working with live commensal microorgan-
isms (probiotics) and increasing safety.
Investigations in the last 1020 years have demon-
strated that gut microorganisms (including probiotic
strains) are capable of breaking down and metabolizing
complex food nutrients and endogenous substances
(saliva, gastro-intestinal juices compounds, epithelial
cells, dead microbial cells, etc.), resulting in the formation
of low molecular weight (LMW) bioactives that may be
localized both inside and/or outside of microbial cells
and found in the intestinal content or passing across
the intestinal epithelial barrier determined in the various
human fluids, organs, and tissues. These compounds,
derived from probiotic (symbiotic) microbes, form what is
called the probiotic metabolome. Interacting with corre-
sponding prokaryotic and eukaryotic cell targets, biolo-
gically and pharmacologically active compounds may
control many genetic, epigenetic, and physiological func-
tions; biochemical and behavior reactions; and intra-
and intercell exchange of information. Some commensal
microbes, including probiotics, can secrete a variety of
signaling molecules that can modify the inter-bacterial
signaling (quorum quenching) and suppress the expres-
sion of virulence genes in pathogens or stimulate the
growth of beneficial indigenous gut microorganisms
(15, 18, 20, 48, 5562). In my opinion, the probiotics
that are commercially available now should be considered
as a first generation of means directed for correction of
microecological disorders.
Further development of traditional probiotics will
include improvements to the present generation by means
of production of natural metabiotics (manufactured
based on current probiotic strains) and synthetic (or
semi-synthetic) metabiotics that will be analogies or
improvized versions of natural bioactives produced by
symbiotic microorganisms. The terms ‘metabiotics’ (4, 20,
63, 64), ‘metabolic probiotics’ (65, 66), ‘postbiotics’ (1),
‘biological drugs’ (10), or ‘pharmacobiotics’ (15) mean
small molecules; they are the structural components of
probiotic (symbiotic) microorganisms and/or their meta-
bolites and/or signaling molecules with a determined
(known) chemical structure that can affect the micro-
biome and/or human metabolic and signaling pathways,
optimizing the composition and function of indigenous
microbiota and host-specific physiology, immunity, and
neuro-hormonbiology, and regulating metabolic and/or
behavior reactions connected with the activity of host
indigenous microbiota. Different probiotic strains can
become the source for hundreds (thousands) of LMW
bioactives - bacteriocins and other antimicrobial mole-
cules, short chain fatty acids, various other fatty and
organic acids, biosurfactants, polysaccharides, peptido-
glycans, teichoic acids, lipo- and glycoproteins, vitamins,
antioxidants, nucleic acids, different proteins including
enzymes and lectines, peptides with various activities,
amino acids, growth and coagulation factors, defensin-
like molecules or their inductors in human cells, messen-
ger (signal) molecules, plasmalogens, various co-factors,
and so on (2, 7, 10, 15, 18, 20, 48, 55, 56, 67). Various
symbiotic (probiotic) strains can produce different sets
of such LMW bioactive molecules, attractive candidates
for metabiotic construction (Table 1).
It should be remembered that the spectrum and
number of bioactives of microbial origin determined in
the different human biological fluids and eukaryotic cells
may also be connected with the activity of the host
transmembrane transporters and/or liver and other tissue
enzymes that can carry or transform various microbial
substances. Metabolomic analysis of plasma extracts
from germ-free and conventional mice (68) as well as
other hosts and gut-microbial co-metabolomes revealed a
significant interplay between gut microflora and mam-
malian metabolism (37).
Specific representatives of these groups of LMW
compounds isolated from symbiotic (probiotic) micro-
organisms or their cultural liquids may be used for
manufacturing microbe-free food supplements, func-
tional foods, and drugs for prophylaxis and treatment
of chronic human diseases, as well as sport and anti-aging
foods, and so on. The aforementioned approaches and
Table 1. Some groups of LMW compounds of symbiotic
(probiotic) microbe origin that may become the basis for
manufacture of potential metabiotics
Bacteriocins
Short-chain fatty acids, other organic acids
Proteins, peptides, amino acids
Nucleic acids, nucleotides
Polysaccharides, peptidoglycans, other cell surface molecules
Plasmalogens, vitamins, antioxidants, co-factors
Various messenger (signal) molecules
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LMW molecules of symbiotic microbiota origin for
nutrition and medicine are already being developed in
some countries (60).
Current probiotic strains may become starter strains for
industrial manufacturing of such microbial bioactive
molecules. The knowledge of quality and quantity of the
LMW molecule profile of each industrially used or
potential probiotic strain will help researchers to design
novel metabiotics with increased health effectiveness, and
determine the optimal frequency, dose, and mode of
administration. Industrial production of metabiotics
could become the novel prophylactic and therapeutic
approach to address human health in the near future
because of their potential ability to interfere in the
processes associated with stability of the host genome
and microbiome; modulation of epigenomic regulation of
gene phenotypic expression in eukaryotic cells; improve-
ment in information exchange, signaling and metabolic
pathways in numerous bacteria, bacteriahost, and host
systems that play an important role in the control of many
genetic, epigenetic, and physiological functions, and
biochemical and behavior reactions; in cell growth and
host development; in supporting host health in general.
We should always remember that real health effectiveness
of suggested metabiotics depends on our knowledge of the
physicochemical characteristics of metabiotic molecules
[molecule isomerism: L or D, and a, b,o rg forms; valency
and isotopic state of incoming chemical elements; sub-
stance solubility; dispersiveness, ligand binding, oxido-
reduction potential of metabiotic ingredient(s), its(their)
interaction with other components that can be both
enhancers or inhibitors; competitive inhibitors for specific
transport proteins or absorption site] as well as host
physiological status, illness, constituents of diet, medica-
tion, and so on.
In biotechnology, the introduction of the concept
‘Metabiotic’ in practice permits inclusion of not only
bifidobacteria, lactobacilli, Escherichia, enterococci strains
but also tens and hundreds of other strains belong-
ing to human-dominant intestinal phyla (Bacteroides,
Firmicutes, Proteobacteria, Actinobacteria, and Archae)
for nutrition and medical aims. There is no doubt that the
future metabiotics created based on the strains belonging
to the wider spectrum of dominant microorganisms may
be more effective at conferring health benefits than the
LMW bioactives received only based on the classical
probiotic strains (bifidobacteria and lactobacilli). The
known and potential microbial starter cultures of human
microbiota origin that could be used as a platform for
metabiotic production should first be investigated on the
synthesis of structural and excreted bioactive substances
participating in or regulating pathways associated with
carbohydrate, fat, and cholesterol metabolism; work of
immune, hormone, and nervous systems; metagenome
and epigenome stability; and gene expression regulation.
Undoubtedly, among human gut microbiota there are
species and strains which are potential sources of small
diffusible antimicrobial agents, regulators of host energy
balance, cholesterol-lowering compounds, modifiers of
immune reactions, stimulants, antidepressants, cognitive
enhancers, and so on. (10, 60, 63). Development of data-
bases of microbe-derived individual compounds orgroups
of compounds provides key information, which could be
used toward a goal-directed design of metabiotics with
specific medical effects. It is also important to remember
that wide rosters of LMW microbial metabolites and
signal molecules produced by microorganisms and deter-
mined in the human physiological fluids can have great
diagnostic value (2, 37, 69, 70). Because in vivo production
of bioactive small molecules of human and microbial
origin is often connected with prebiotic-stimulated sec-
ondary metabolism (8, 10), it would be sensible to design
combined metabiotic/prebiotic foods and drugs for nutri-
tional and medical purposes and prescription targeted to
host microbiota or to indigenous microflora associated
host functions, metabolic and behavior reactions.
Known and potential metabiotics
Some metabiotics based on natural (or artificial) bioac-
tives of microbial origin have already been introduced in
the last decade into medical practice and have proven
their effectiveness in reducing infectious and metabolic
diseases. For example, currently, in the international
drug market, the most well-known metabiotic is ‘Hylak
Forte’ (Ratiopharm/Merckle, Germany. Code EAN:
4030096245166; N P No1497/01, 2009-05-14). This bac-
teria-free liquid medicine for oral use contains metabolic
products of Escherichia coli DSM 4087 (25 g), Streptococ-
cus faecalis DSM 4086 (12.5 g), Lactobacillus acidophilus
DSM 4149 (12.5 g), and L. helveticus DSM 4183 (50 g).
The benefits of this sterile liquid drug are explained by the
presence of SCFA, lactic acid, and some other non-
identified microbial metabolites in this drug. Data prove
that ‘Hylak Forte’ has health benefits for adults and
children by producing positive shifts in intestinal micro-
biota, host acidalkaline balance, watersalt metabolism,
vitamins B and K balance, and energy provision to
intestinal epithelia and local immune cells (71). Other
notable commercial metabiotics are ‘Zakofalk’ (a combi-
nation of sodium butyrate and inulin) recommended for
the treatment of mild to moderately active inflammatory
intestinal diseases (72); E. coli glycoprotein with anorexic
activity (73); Lactobacillus casei (LEx) polysaccharide 
glycopeptide with antihypertension effect (74, 75);
L. helveticus three-peptides (Val-Pro-Pro and Ile-Pro-
Pro) inhibiting angeotensin convert enzyme (ACE) and
resulting in the decrease of blood pressure (76, 77);
lyophilizedB.subtilisbacteria-freeculturefluidcontaining
lysozyme, catalase, polypeptides, peptidoglycan, amino
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and gut microbiota-restoring activity (‘bactistatin’) (78;
www.stada.ru/products/baktistatin.html); lactic acid bac-
teriaSCFAandotherorganicacids(‘Solcarmon’,‘Frodo’)
(79); and Quorum sensing Escherichia, lactobacilli and
bifidobacteria autoregulators of growth and development
of indigenous intestinal microflora (65, 66). Potential
metabiotics on the basis of lactobacilli, bifidobacteria,
enterococci proteins, peptides, adhesions (55, 56), biosur-
factants (more than 30kD) (80), lectines (81, 82), nucleic
acids, and various cell wall molecules (15) connected with
microbial cells or produced in cultural liquid possessing
various host effects are now under development. Special
attentionshouldbepaidtomicrobialmembranesterol-like
compounds (e.g. plasmalogens) (59) and outer mem-
brane lipoproteins (e.g. lipocalins) (83, 84) as attractive
candidate molecules for the manufactureofdifferent types
of metabiotics that are capable of inhibiting lipid and
energymetabolism,immune,hormoneandnervoussystem
functions.
Metabiotics, as modifiers of physiological functions,
biochemical and behavior reactions, have some advan-
tages such as chemical structure, dosage, safety, and long
shelf-life. Besides, metabiotics possess better absorption,
metabolism, distribution, and excretion abilities com-
pared with classic probiotics based on live microorgan-
isms. A detailed molecular understanding of metabiotics
can turn them into significant, specific, and active
contributors to the benefits derived from probiotics (4,
10, 15, 20).
If a manufacturer tries to label a metabiotic product
with specific therapeutic claims (prevents or treats a
specific disease or improves a specific function or
metabolic reaction), such metabiotics must be regulated
as a drug needing approval by individual national and
international agencies controlling quality and safety of
food and drugs.
Conclusion
Metabiotics are no longer a myth; they are a natural
evolution of the probiotic conception. In the near future,
based on probiotic LMW bioactives with proven specific
beneficial effect(s), a set of semi- and/or completely
synthetic metabiotics will be designed that are analogies
or improved versions of the natural microbial bioactives.
This is a similar route of development as in the case of
traditional antibiotics which have been in production
during the past 50 years. LMW bioactives of indigenous
microbiota origin being chemically similar with the
molecules of other origin (e.g. from food raw materials
orfoodstuffs) haveadvantagesinprinciple.For millionsof
years of evolution, the human superorganism has been
selecting prokaryotic and eukaryotic microorganisms
from the environment that were functionally and metabo-
lically the most optimal for human life and development.
It means that metabiotics manufactured based on the
LMW bioactives of indigenous microbiota origin are the
most beneficial and the safest.
The metabiotics of the future will promote further
development of the probiotic concept, improve effective-
nessandbenefitspecificityofclassicprobiotics,andreduce
environmental and health hazards of the current micro-
ecological approaches in the prevention and treatment of
diseases associated with imbalance of host microbiota.
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